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ABSTRACT
Background and Aims Take-home naloxone can prevent death from heroin/opioid overdose, but pre-provision is
difﬁcult because naloxone is usually given by injection. Non-injectable alternatives, including naloxone nasal sprays, are
currently being developed. To be effective, the intranasal (i.n.) spray dose must be adequate but not excessive, and early
absorption must be comparable to intramuscular (i.m.) injection. We report on the pharmacokinetics (PK) of a specially
produced concentrated novel nasal spray. The speciﬁc aims were to: (1) estimate PK proﬁles of i.n. naloxone, (2) compare
early systemic exposure with i.n. versus i.m. naloxone and (3) estimate i.n. bioavailability. Design Open-label, random-
ized, ﬁve-way cross-over PK study. Setting Clinical trials facility (Croydon, UK). Participants Thirty-eight healthy vol-
unteers (age 20–54 years; 11 female). Intervention and comparator Three doses of i.n. (1 mg/0.1 ml, 2 mg/0.1 ml,
4 mg/0.2 ml) versus 0.4 mg i.m. (reference) and 0.4 mg intravenous (i.v.) naloxone. Measurements Regular blood
samples were taken, with high-frequency sampling during the ﬁrst 15 minutes to capture early systemic exposure. PK
parameters were determined from plasma naloxone concentrations. Exploratory analyses involved simulation of repeat
administration. Findings Mean peak concentration (Cmax) values for 1 mg (1.51 ng/ml), 2 mg (2.87 ng/ml) and
4 mg (6.02 ng/ml) i.n. exceeded 0.4 mg i.m. (1.27 ng/ml) naloxone. All three i.n. doses rapidly achieved plasma levels
> 50% of peak concentrations (T50%) by 10 minutes, peaking at 15–30 minutes (Tmax). For comparison, the i.m. refer-
ence reached Tmax at 10 minutes. Mean bioavailability was 47–51% for i.n. relative to i.m. naloxone. Simulation of repeat
dosing (2 × 2 mg i.n. versus 5 × 0.4 mg i.m. doses) at 3-minute intervals showed that comparable plasma naloxone con-
centrations would be anticipated. Conclusions Concentrated 2 mg intranasal naloxone is well-absorbed and provides
early exposure comparable to 0.4 mg intramuscular naloxone, following the 0.4 mg intramuscular curve closely in the
ﬁrst 10 minutes post-dosing and maintaining blood levels above twice the intramuscular reference for the next 2 hours.
Keywords Antidote, drug overdose, intranasal, naloxone, nasal, opiate, opioids, pharmacokinetics.
Correspondence to: John Strang, National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 4 Windsor Walk,
London SE5 8BB, UK. E-mail: john.strang@kcl.ac.uk
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*This study was performed according to the Declaration of Helsinki (1964), International Conference on Harmonization and Good Clinical Practice (CPMP/
ICH/135/95) guidelines of the EMA and European Union Clinical Trials Directive 2001/20/EC.
[Correction added on 9 Feb 2018, after ﬁrst online publication: Tylleskar et al. (2017) was missing from the reference list and is updated in this version.]
INTRODUCTION
Overdose deaths from heroin and other opioids represent a
signiﬁcant international public health concern, account-
ing for approximately 106000 deaths annually [1]. In
2014, the World Health Organization (WHO) launched
guidelines [2] recommending that ‘people likely to witness
an opioid overdose should have access to naloxone’ (p. x).
However, pre-provision has been difﬁcult, because nalox-
one is usually available only in injectable form.
The development of nasal naloxone spray for layperson
use was ﬁrst mooted in the late 1990s [3]. During the
2000s, various groups began introducing improvised nasal
spray kits, consisting of a syringe pre-ﬁlled with the most
concentrated injectable naloxone solution available
(1 mg/ml) and a Mucosal Atomisation Device [4]. While
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their use has been criticized for the absence of supporting
pharmacokinetic (PK) data [5,6], it undoubtedly
established the potential worth of nasal naloxone. In the
United States, a step-change occurred in 2012 with the
joint initiative of the US Food and Drug Administration
(FDA), Centers for Disease Control and Prevention (CDC)
andNational Institute on DrugAbuse (NIDA) to encourage
non-injectable naloxone formulations, alongside FDA clar-
iﬁcation of the regulatory benchmark: one or multiple
doses of non-injectable formulation must result in similar
or greater naloxone exposure than a 0.4mg intramuscular
(i.m.) reference [7]; i.m. naloxone reverses opioid overdose
rapidly, with adequate respiration resuming typically
within 3–7 minutes [8]. For new non-injectable formula-
tions, the early absorption curve is thus crucial, corre-
sponding to the time-frame during which i.m. naloxone
reaches peak concentration.
The FDA and Health Canada approved a ﬁrst nasal
naloxone product in November 2015 [9–11] and October
2016 [12], respectively. However, only limited PK data for
intranasal (i.n.) naloxone exist to date [11,13,14,30], with
bioavailability estimates ranging from 4% for dilute [2 mg/
5 ml relative to intravenous (i.v.)] [11] to 46–54% for
concentrated (0.8 mg/0.1 ml relative to i.v.; 4 mg/0.1 ml
relative to i.m.) formulations [14,30] [Correction added
on 9 Feb 2018, after ﬁrst online publication: Pharmacoki-
netics of a naloxone nasal spray formulation of intermedi-
ate concentration values were missing and are updated in
this version].
Recent work in Europe has explored different i.n.
formulations, with the objective of developing a nasal spray
suitable for lay administration, aiming for rapid onset of
action and adequate exposure, without risk of ‘over-
antagonism’ [7,15,16,30]. We now report on the PK char-
acteristics of nasal naloxone spray at different concentra-
tions and doses, with particular focus on early absorption.
The primary aims of this study were to (1) estimate the
PK proﬁle of i.n. naloxone and (2) compare its early partial
systemic exposure to the i.m. reference. The secondary aim
was to (3) estimate i.n. bioavailability.
METHODS
Study design
A randomized, open-label, ﬁve-way cross-over study
(EudraCT number: 2015–004493-15) in healthy volun-
teers was conducted at Richmond Pharmacology (Croydon
University Hospital, UK) to determine naloxone pharmaco-
kinetics from highly concentrated nasal spray solution
(10 mg/ml, 20 mg/ml; Summit Biosciences, Lexington,
KY, USA) at three doses; i.n. naloxone was administered
as atomized spray with the unit dose system (Aptar
Pharma, Cary, IL, USA). Laser diffraction determined that
the size of ≥ 94% of droplets was greater than 10 μm to
ensure deposition of the spray in the nasal cavity.
The reference routes were i.m. (primary reference) and
i.v. administration of proprietary naloxone hydrochloride
solution (Braun Melsungen, Melsungen, Germany).
The ﬁve study sessions comprised: (a) 1 mg naloxone
i.n. (1 mg/0.1 ml i.n. one nostril); (b) 2 mg naloxone i.n.
(2 mg/0.1 ml i.n. one nostril); (c) 4 mg naloxone i.n.
(2 mg/0.1 ml i.n. each nostril); (d) 0.4 mg naloxone i.m.
(0.4 mg/ml into the deltoid) and (e) 0.4 mg naloxone i.v.
(0.4 mg/ml into the ante cubital fossa).
The i.n. dose range was based on our earlier analysis,
which identiﬁed 1–4 mg i.n. as producing potentially
similar early naloxone exposure to 0.4–0.8 mg i.v. [13].
With sequence assigned randomly in a cross-over
design, each subject received all ﬁve study treatments, with
a single naloxone dose per session (see Supporting informa-
tion, Fig. S1). Each session was separated by a minimum
4-day washout period. Dosing occurred in the fasting state.
Subjects were in a fully supine position, remaining supine
for at least 1 hour post-dose and semi-supine thereafter
until at least 4 hours post-dose.
Blood sampling and chemical analysis
Given the special interest in early absorption, blood collec-
tion included intense sampling during the ﬁrst 15minutes,
with a total of 19 samples per session (pre-dose, at 1, 2, 4,
6, 8, 10, 12.5, 15, 30 and 45minutes and 1, 1.5, 2, 4, 6, 8,
10 and 12 hours after dosing). Blood samples were centri-
fuged (1500 × g, 4°C, 15 minutes) within 30 minutes of
collection, with plasma stored (20°C) within 1 hour.
Naloxone plasma concentrations were quantiﬁed by liquid
chromatography–tandem mass spectrometry (LC–MS/MS)
methodology using a previously validated assay.
Pharmacokinetic analysis
Individual subject PK parameters for naloxone were
derived using non-compartmental analysis in Phoenix
WinNonlin version 6.4 (Certara LP, Princeton, NJ, USA),
a validated PK analysis program. The area under the
concentration–time curve (AUCt) was determined using
the linear-up/log-down trapezoidal method from dosing
(0 h) to the ﬁnal observed plasma concentration (Clast)
for AUCt. The ratio of Clast to LambdaZ was used to esti-
mate the area between the last measured time-point and
inﬁnity and added to AUCt to yield AUCINF. The maximum
observed plasma concentration (Cmax) and the time to Cmax
(Tmax) were obtained directly from plasma concentration
data. LambdaZ was estimated using points in the terminal
log-linear phase, and terminal phase half-life (t1/2Z) was
determined from the ratio of the natural logarithm of 2 to
LambdaZ.
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Bioavailability
Dose-adjusted AUC data (per mg) from i.n. administration
were compared against the 0.4 mg i.m. and i.v. reference
doses. Mean bioavailability estimates were determined for
subjects for whom paired data were available.
Exploratory analyses
Exploratory analyses were conducted additionally to con-
sider early exposure relative to the i.m. reference and repeat
naloxone administration.
Early naloxone absorption
Given that Tmax may not describe the early absorption
curve fully [5], three exploratory PK parameters were
introduced to assess early exposure from i.n. relative to
0.4 mg i.m. naloxone: t50% [deﬁned as time taken to
achieve blood levels of 50% of Cmax (C50%)] [5]; AUCp
(partial AUC from time of dosing to median Tmax of i.m.
naloxone); and, for i.n. administration, T50%ref (time taken
to reach the C50% of the primary reference 0.4 mg i.m.).
Simulation of repeat administration
In emergencymedicine, naloxone dosesmay be repeated to
achieve overdose reversal. Therefore, simulations of repeat
administrations were performed using the superposition
approach. Superposition relies upon linear pharmacokinet-
ics and employs a simple overlay technique, assuming that
observed plasma concentrations after a single dose can be
used to predict plasma concentrations after multiple dosing
[17]. Opioid overdose management guidelines typically
recommend initial administration of 0.4 mg naloxone,
repeated every 2–3 minutes if necessary [7,16,18,19].
Consequently, we simulated repeat administration of ﬁve
doses of the 0.4 mg i.m. reference at 3-minute intervals
(simulating the upper limit of the recommended dose
range, 2 mg i.m.) versus two doses of 2 mg i.n. at 3-minute
intervals (simulating similar naloxone exposure, assuming
50% i.n. bioavailability).
Simulation of immediate administration of the full dose
In the crisis situation, non-medical ﬁrst responders may
forget or ignore instructions and administer the full avail-
able dose. We therefore also scaled the observed PK curves
to doses of 5 × 0.4mg i.m. and 2× 2mg i.n., the total doses
that would be available for a ﬁrst responder to administer.
Protection of human subjects
Approval was given by South Central–Berkshire B
Research Ethics Committee (Reading, UK). All subjects
provided written informed consent.
Sample size
The sample size was calculated on the basis that 28
evaluable subjects would provide approximately 80–90%
power for detecting 90% conﬁdence intervals of the ratio
between treatment in pharmacokinetic parameters with
bounds lying completely between 80–125%, assuming a
true ratio of 1 and a standard deviation between 0.35–0.4
for the period differences on log scale. It was assumed that
up to 20% of subjects might not be part of the primary anal-
ysis population or yield valid PK parameters for analysis of
each of the ﬁve study treatments. Hence, at least 35 subjects
were planned to be enrolled and analysed.
Subject eligibility
Eligible volunteers (female and male) had to be aged
18–55 years, body weight 55–100 kg, BMI ≥ 18.5 and
≤ 30.0 and healthy, i.e. free of signiﬁcant abnormal ﬁndings
as determined by medical history, physical examination,
vital signs, laboratory tests and electrocardiograph (ECG).
Volunteers were excluded if they had abnormal nasal
anatomy, nasal symptoms (e.g. polyps, blocked/runny
nose) or history of hayfever/seasonal allergy/rhinitis.
Female volunteers were excluded if pregnant or lactating.
Statistical analysis
Randomization to one of ﬁve treatment sequences was per-
formed by the study sponsor (Mundipharma Research Ltd,
Cambridge, UK) using validated software (Random Patient
Allocation System, Episys Ltd, Letchworth, UK) that auto-
mates the random assignment of treatment sequences to
randomization numbers. The randomization scheme was
reviewed by the sponsor’s statistics department and locked
after approval. Randomization was completed once eligibil-
ity was veriﬁed and occurred between day1 and prior to
ﬁrst dosing (day 1). Randomization order was determined
on a central randomization list held at site.
Descriptive statistics for pharmacokinetic outcomes
were calculated using SAS software.
RESULTS
Study participants
Thirty-eight subjects (age 20–54 years) were randomized,
27 of whom were male and 11 were female. Prior to period
2 dosing there were four subject discontinuations (three
subjects tested positive for drugs of abuse, one subject
withdrewconsent). As the protocol allowed for replacement
subjects, it was agreed to randomize three additional sub-
jects to the next available treatment sequence in the ran-
domization schedule, and therefore the original enrolment
target of 35 subjects was exceeded. In total, six subjects
did not complete the study (see Supporting information,
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Fig. S1): six missed the 0.4 mg i.m. session; ﬁve missed the
1 mg i.n. session, four missed the 4 mg i.n. and 0.4 mg i.v.
sessions, and two missed 2 mg i.n. session. These 21 ses-
sions were handled as missing data. Consequently, values
reported below refer to sample sizes of n = 32 (0.4 mg i.
m.), n = 33 (1 mg i.n.), n = 34 (4 mg i.n., 0.4 mg i.v.) and
n = 36 (2 mg i.n.), unless speciﬁed otherwise.
Safety
No severe adverse events (AEs) occurred. In total, 17 (of
n = 38) subjects experienced 24 AEs (see Supporting infor-
mation, Table S1), of which 11 AEs in nine subjects were
assessed as naloxone-related. AE-occurrence did not seem
to be dose-related: seven subjects experienced AEs after
2 mg i.n. dose, while only three subjects experienced AEs
after 4 mg i.n. dose.
Pharmacokinetic proﬁles
PK parameters are shown in Table 1. Mean plasma nalox-
one concentrations during the ﬁrst 2 hours post-dosing are
displayed in Fig. 1 (left-hand side), including expanded de-
piction of the ﬁrst 20 minutes (right-hand side).
Plasma concentration following i.v. administration
(0.4 mg) spiked and reached an early peak (geometric
mean Cmax 5.94 ng/ml, median Tmax 2 minutes), followed
by a rapid decline during the next 10 minutes and a grad-
ual decline thereafter.
The i.m. administration (0.4 mg) showed more gradual
early uptake, with lower and later peak (geometric mean
Cmax 1.27 ng/ml, median Tmax 10 minutes), and ﬂatter
and slower decline thereafter. Overall AUCt-based exposure
was comparable for i.m. and i.v. All i.n. doses (1 mg,
2 mg, 4 mg) achieved maximum plasma levels within
15–30 minutes (median Tmax). Geometric mean Cmax
values for 1 mg i.n. (1.51 ng/ml), 2 mg i.n. (2.87 ng/ml)
and 4 mg i.n. (6.02 ng/ml) were greater than for i.m..
For all three i.n. doses, geometric mean AUCt values
(2.56–10.01 h × ng/ml) exceeded those of 0.4 mg i.m.
and i.v. (both: 2.01 h × ng/ml). Of the three i.n. doses, the
2 mg dose followed the 0.4 mg i.m. curve most closely dur-
ing the ﬁrst 10 minutes post-dose, reached blood levels at
twice the 0.4 mg i.m. dose by 15 minutes and maintained
blood levels at more than twice the 0.4 mg i.m. dose for
the next 2 hours. Individual proﬁles for the 2-mg dose are
also provided to display individual variation (see Fig. 2;
see Supporting information, Fig. S2 for other doses).
Intranasal bioavailability
The mean absolute bioavailability (F%) estimates for i.n.
naloxone (i.e. relative to i.v.) from dosing to last
measureable concentration (AUCt) were 50.2% (1 mg
i.n.; n = 32), 46.8% (2 mg i.n.; n = 33) and 48.1% (4 mg
i.n.; n = 33); see Table 2; i.n. administration had a mean
bioavailability relative to i.m. (Fi.m.%) of 50.8% (from
1 mg i.n.), 47.1% (2 mg i.n.) and 48.3% (4 mg i.n.), also
determined from AUCt data (all n = 32).
Exploratory analyses
As it followed the 0.4 mg i.m. reference most closely
(see above), the 2 mg i.n. dose was chosen as comparator
against the i.m. reference in exploratory analyses.
Table 1 Pharmacokinetic parameters.
Parameter Unit 1 mg i.n. 2 mg i.n. 4 mg i.n. 0.4 mg i.m. 0.4 mg i.v.
AUCt
Geometric mean (CV%) Hour × ng/ml 2.56 (43.2) 4.86 (39.4) 10.01 (35.8) 2.01 (17.7) 2.01 (22.5)
Arithmetic mean (SD) Hour × ng/ml 2.78 (1.2) 5.21 (2.0) 10.57 (3.5) 2.04 (0.4) 2.05 (0.4)
Range (min, max) Hour × ng/ml 1.15, 5.78 2.33, 11.23 3.96, 21.08 1.31, 2.92 1.00, 3.12
AUCINF
Geometric mean (CV%) Hour × ng/ml 2.69 (40.5) 4.97 (38.5) 10.07 (35.8) 2.12 (16.6) 2.10 (21.1)
Arithmetic mean (SD) Hour × ng/ml 2.90 (1.2) 5.31 (2.0) 10.64 (3.5) 2.15 (0.3) 2.14 (0.4)
Range (min, max) Hour × ng/ml 1.23, 5.88 2.44, 11.35 4.05, 21.12 1.37, 3.05 1.06, 3.35
Cmax
Geometric mean (CV%) ng/ml 1.51 (50.2) 2.87 (49.6) 6.02 (54.5) 1.27 (55.8) 5.94 (92.9)
Arithmetic mean (SD) ng/ml 1.27 (0.7) 3.18 (1.5) 6.84 (4.0) 1.42 (0.6) 7.93 (6.0)
Range (min, max) ng/ml 0.42, 3.49 1.24, 7.50 1.72, 24.60 0.35, 2.38 1.17, 21.9
LambdaZa 1/hour 0.55 (0.1) 0.53 (0.1) 0.44 (0.1) 0.53 (0.1) 0.57 (0.1)
t1/2Z
a Minute 80 (23) 84 (30) 102 (28) 81 (16) 75 (13)
HVDa Minute 79 (40) 76 (33) 75 (38) 65 (67) 8 (12)
Tmax
b Minute 15 (10, 60) 30 (8, 60) 15 (10, 60) 10 (4, 90) 2 (1, 15)
AUCt = area under the curve (AUC) up to last measurable time point; AUCINF = AUC up to inﬁnity; Cmax = maximum observed plasma concentration;
LambdaZ = terminal phase rate constant; t1/2Z = terminal phase half-life; HVD = half-value duration; Tmax = time to Cmax.; i.n. = intranasal; i.m. = intramus-
cular. aArithmetic mean [standard deviation (SD)]; bmedian (min, max). CV = coefﬁcient of variation.
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Early naloxone absorption
Given our special interest in early uptake, we examined
AUCp, T50% and T50%ref for the early part of the plasma
concentration–time proﬁles for i.n. naloxone relative to
the i.m. reference (see Table 3).
• AUCp: the rounded partial AUC values, measured from
dosing to Tmax of the i.m. reference, were identical for
both 0.4 mg i.m. and 2 mg i.n. (geometric mean:
0.11 h× ng/ml).
• T50%: i.m. achieved plasma levels > 50% of Cmax
(C50%) at 4 minutes. The 2 mg i.n. dose took 9 minutes
to reach C50%.
• T50%ref: the 2 mg i.n. dose achieved concentrations
equivalent to C50% of the i.m. reference at 6 minutes,
i.e. within 2 minutes of the i.m. reference, suggesting
that early i.n. and i.m. naloxone plasma concentrations
did not differ greatly.
Simulation (1) repeat administration
To explore the pharmacokinetics of repeated administra-
tion, i.n. bioavailability (relative to i.m., as reported above)
in the range of 47–51%, hence a 2 : 1 dose ratio (i.n. : i.m.)
was assumed for the simulations, comparing cumulative
2 × 2 mg i.n. doses at 3-minute intervals with ﬁve
Figure 1 Mean plasma naloxone concentrations (observed values): dosing to 120 minutes (left) and dosing to 20 minutes (right)
Figure 2 Plots of plasma naloxone concentrations over time (left: 120 minutes; right: 20 minutes) for individual subjects after 2 mg intranasal
(i.n.) dose
Table 2 Absolute (F%) and relative (Fi.m.%) mean bioavailability (90% conﬁdence interval) based on area under the curve up to last
measurable time-point.
Reference n 1 mg i.n. 2 mg i.n. 4 mg i.n.
Fi.m.% 0.4 mg i.m. 32 50.8 (45.2, 57.1) 47.1 (41.5, 53.5) 48.3 (43.2, 54.1)
F% 0.4 mg i.v. 32–33 50.2 (44.6, 56.6) 46.8 (41.7, 52.6) 48.1 (43.3, 53.5)
i.n. = intranasal; i.m. = intramuscular.
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cumulative 0.4 mg i.m. doses at 3-minute intervals (total
2 mg i.m.).
Figure 3 shows the peak plasma level from the observed
2 mg i.n. dose occurring between those from the observed
i.m. 0.4 mg dose and the simulated 2 mg i.m. dose
(5 × 0.4 mg administered 3 minutes apart). This simula-
tion suggests that, in a hypothetical overdose scenario, a
second dose of 2 mg i.n. administered after 3 minutes
would expose the patient to approximately the same
plasma naloxone levels, in terms of both initial rise and
peak, as ﬁve consecutive i.m. 0.4 mg doses (also 3 minutes
apart), i.e. 2 mg in total.
In addition, the plasma naloxone levels from the
simulated 2 × 2 mg i.n. dose declined more slowly than
the simulated × 0.4 mg i.m. administrations, indicating
that plasma naloxone concentrations would be sustained
for longer than those from i.m. dosing.
Simulation (2) immediate multiple dose administration of
the full dose
The observed PK proﬁles, scaled in dose, were used to
explore the pharmacokinetics of possible unintended
immediate administration of the full 2 mg i.m. injection
(i.e. all ﬁve 0.4 mg doses up to the top of approved
therapeutic dose range) versus two simultaneous 2 mg
i.n. doses (see Fig. 4). The scaled concentration data indi-
cate that the 2 mg i.m. dose would have the fastest speed
of uptake. In addition, the scaled 4-mg proﬁle (two 2 mg
i.n. doses) was compared with the observed data from the
4 mg i.n. dose (administered as 2 mg per nostril) and
lagged only slightly behind the observed 4 mg i.n. proﬁle.
However, in terms of dose-adjusted AUC, the three admin-
istrations (2 mg i.m., 2 × 2mg i.n., 4 mg i.n.) were roughly
equivalent.
DISCUSSION
Principal ﬁndings
Our recent report of analysis of previously unpublished PK
data established proof-of-concept for i.n. administration
of concentrated naloxone formulations [13]. The results
of this new investigation conﬁrm i.n. naloxone bioavailabil-
ity of approximately 50% (relative to i.m.), thus markedly
different from the 4% absolute bioavailability reported by
Dowling et al. [14], yet very similar to the 46% relative bio-
availability reported by Krieter et al. for the FDA/Health
Canada-approved product (4 mg/0.1 ml) [11]. Our results
suggest feasibility of concentrated naloxone nasal spray at
Table 3 Exploratory pharmacokinetic parameters.
Parameter Unit 1 mg i.n. 2 mg i.n. 4 mg i.n. 0.4 mg i.m. 0.4 mg i.v.
AUCp
Geometric mean (CV%) Hour × ng/ml 0.05 (112.2) 0.11 (105.1) 0.27 (98.6) 0.11 (67.9) 0.44 (56.2)
Arithmetic mean (SD) Hour × ng/ml 0.07 (0.1) 0.15 (0.1) 0.36 (0.3) 0.13 (0.1) 0.50 (0.2)
Range (min, max) Hour × ng/ml 0.00, 0.21 0.01, 0.56 0.04, 1.52 0.03, 0.28 0.07, 1.12
T50%a Minute 10 (5) 9 (4) 9 (5) 4 (1) 1 (1)
T50%ref
a Minute 10 (8) 6 (4) 4 (2) (4 (1)) 1 (2)
aArithmetic mean (standard deviation). AUCp = partial area under the curve with cut-off at Tmax of reference; T50% = time to 50% of Cmax; T50%ref = time to
C50% of 0.4 mg i.m. (primary reference); i.n. = intranasal; i.m. = intramuscular; i.v. = intravenous; SD = standard deviation; CV% = coefﬁcient of variation.
Figure 3 Scaled mean plasma naloxone concentrations after repeat
administration at 3-minute intervals (versus mean observed proﬁles of
0.4 mg intramuscular (i.m.) and 2 mg intranasal (i.n.) doses)
Figure 4 Scaled mean plasma naloxone concentrations after immedi-
ate administration of multiple doses at 0 minutes (versus mean observed
proﬁle of 4 mg intranasal (i.n.) dose)
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three doses (1 mg/0.1 ml; 2 mg/0.1 ml; 4 mg as 2 × 2
mg/0.1 ml) for use by non-medical ﬁrst-responders. Across
these doses, naloxone plasma concentrations increased
rapidly, with median peak concentrations between 15
and 30 minutes. This is consistent with Tmax values of
18–30 minutes reported for concentrated i.n. naloxone
(also 0.1 ml volume) by Krieter et al. and by Tylleskar et
al. [11,30], and conﬁrms that i.n. naloxone is absorbed rap-
idly into the systemic circulation via the nasal mucosa
[Correction added on 9 Feb 2018, after ﬁrst online publica-
tion: Tmax values are updated in this version to include
those reported by Tylleskar et al. (2017).]. In the present
study, the 2 mg/0.1 ml i.n. dose resulted in early uptake
and exposure similar to the 0.4mg i.m. reference, reaching
concentrations equivalent to C50% of 0.4 mg i.m. within 2
minutes of the i.m. reference (T50%ref: 4 versus 6 minutes;
see Table 3), suggesting that i.n. naloxonemay be a feasible
alternative to an i.m. injection.
The low bioavailability reported by Dowling et al. [14]
was due probably to use of dilute (2 mg/5 ml) naloxone
solution for injection which led to administration of high
volumes—far in excess of what can be absorbed nasally
without signiﬁcant loss from the nasal cavity or post-nasal
drip. Low bioavailability of dilute nasal sprays is also seen in
a recent conference report [20] and data contained in
patent registrations [21].
As for the shape of the PK curves following all i.n.
naloxone doses, there is reasonably rapid early absorption,
followed by good maintenance of plasma levels throughout
the period of time reported. This is in sharp contrast to i.v.
(where the sudden rise in plasma level is followed by rapid
decline) and i.m. administration (whichmainly differs from
the i.v. curve by lacking the initial spike). If i.m. is the refer-
ence route of administration then, after dose-adjustment,
concentrated nasal naloxone appears to offer comparable
early onset followed by better maintenance of plasma levels
during the intermediate period.
The 2-mg i.n. dose produced speed of onset and early
exposure comparable to 0.4 mg i.m. dose, while maintain-
ing plasma levels for the next 2 hours at twice the level of
the i.m. reference. Plasma concentrations from 2 mg in
exceeded those from 0.4 mg i.m. within 6 minutes post-
dosing on average. The focus on this 2 mg i.n. dose may
be particularly applicable to emergency administration
using a dose-escalation schedule as recommended with
i.m. doses [16,18,19], starting at 0.4 mg and increased at
intervals (e.g. 3-minute intervals) to a total of 2 mg. A
comparable i.n. dose-escalation schedule would involve
an initial 2 mg dose to achieve onset comparable to i.m.
0.4mg, followed by a second 2mg i.n. dose 3minutes later;
this is the hypothetical schedule examined in the repeat-
dosing simulation. As the second i.n. dose is given to the
unused nostril, absorption from both administrations
should be equal, and the similarity between the simulation
and the 4 mg tested dose supports this assumption.
Furthermore, the sustained plasma concentrations for the
2 mg i.n. dose compared with the i.m. reference may ben-
eﬁt post-resuscitation care. Given that the half-life of some
opioids exceeds substantially that of naloxone (1–1.5 h)
[2], sustained plasma naloxone concentrations from i.n.
administration would probably reduce the risk of rebound
toxicity when naloxone concentrations drop following i.v.
or i.m. administration.
Strengths and limitations of the study
Strengths
Our particular focus has been the study of concentrated
naloxone nasal spray to identify a dose and formulation
comparable to i.m. 0.4 mg and similarly appropriate for
dose-titration, as recommended currently for the i.m. dose.
Our exploratory dose simulations indicate that a 2-mg i.n.
dose provides opportunity for titration, with administration
of a second 2-mg i.n. dose resulting in naloxone exposure
similar to a series of ﬁve i.m. 0.4 mg doses (i.e. 2 mg i.m.
in total). Such an i.n. schedule would straddle the overall
dose range of an ‘initial [injectable] dose between
0.4 mg–2 mg’, as recommended by WHO [2].
The possibility of incremental dose titration presents
distinct advantages, as it could reduce signiﬁcantly the risk
of adverse reactions. High initial naloxone doses may
trigger severe sudden-onset opioidwithdrawal [2,22]. A re-
cent qualitative analysis of cases of heroin/opioid overdose
reversals identiﬁed apparent excessive naloxone dosing
(‘over-antagonism’), sometimes triggering patient self-
discharge and active further drug-seeking [15]. In addition
to pharmacological toxicity, such ‘behavioural toxicity’
needs to be considered. Withdrawal symptoms can be par-
ticularly challenging for overdose witnesses to manage in
the community setting. Simulation of repeat administra-
tion of the 2 mg i.n. dose produced roughly equivalent
plasma naloxone levels to a single 4-mg i.n. dose. Giving
a single 2 mg i.n. dose at ﬁrst and following up with a
second 2 mg i.n. dose only if needed could lower the risk
of naloxone ‘over-antagonism’ and improve the safety of
the overdose victim and those attending the overdose
scene. In addition, if naloxone doses trigger frequent severe
withdrawal symptoms, then there is a real danger that,
despite its life-saving value, naloxone may be viewed as a
punitive medication that is to be avoided, as was the
perspective ofmanyoverdose patients interviewed byNeale
[15]. This might be regarded as ‘reputational toxicity’.
Limitations
While our ﬁndings support good early absorption and
overall bioavailability in healthy subjects, concentrated
naloxone nasal spray has yet to be tested formally in the
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target population of opioid users. Nasal naloxone might be
absorbed differently by opioid users due to compromised
nasal mucosa (e.g. chronic ulceration from drug snorting
[23]) or nasal obstruction from either mucus or vomit
during overdose [5]. At a practical level, it is challenging
to quantify the impact of nasal congestion and compro-
mised nasal mucosa, both in terms of possible lack or
potentiation of absorption [24]. Preliminary clinical
evidence from anAustralian ambulance-based randomized
trial [25] suggests that risk of modiﬁed absorption of i.n.
naloxone may be small: in patients with suspected opioid
overdose (n = 155) assigned to treatment of 2 mg/5 ml
i.n. versus 2 mg/2 ml i.m. naloxone, there was no
signiﬁcant group difference regarding the need for a rescue
injection of naloxone. However, statistical power for this
comparison was limited, pointing to the potential need for
replication of this study in a larger sample size.
Implications of results for practice and health policy
In recent years, international clinical practice has seen a
shift from i.v. to i.m. naloxone for greater ease of adminis-
tration, given that venous access can be difﬁcult to
establish in long-term injecting drug users [18]; i.v. admin-
istration leads to immediate increase of plasma naloxone
concentrations with early Tmax, high Cmax and rapid
decline thereafter. By comparison, i.m. administration
produces slower absorption (i.e. later Tmax) and lower Cmax.
However, the i.m. proﬁle is now increasingly considered to
be therapeutically beneﬁcial: it avoids the extreme spike
of i.v. naloxone but still attains efﬁcacious plasma levels
within the ﬁrst minutes post-dosing; we have additionally
studied the T50% parameter for this very reason. Further-
more, the longer duration of effect of i.m. naloxone is
considered beneﬁcial [26].
Overall, the results of this study point to the worth of
concentrated i.n. spray for opioid overdose reversal. The
2mg i.n. dose provided comparable rate and extent of early
exposure to the 0.4 mg i.m. reference, but maintained
plasma levels at the approximate level of two 0.4 mg i.m.
doses for more than 2 hours post-dosing.
The use of i.n. may offer advantages over injectable nal-
oxone formulations. First, i.n. naloxone removes the risk of
needle-stick injury and contraction of blood-borne diseases
(e.g. hepatitis C, HIV), which are highly prevalent among
this patient group [27]. Secondly, as i.n. naloxone does
not require training in needle-and-syringe assembly, it
enables laypeople to administer naloxone safely and could
thus be pre-provided to a much wider intervention work-
force (including hostel staff, outreach workers, police).
Thirdly, injectable medicinal products are subject to
prescription according to Article 71 of the EU Medicinal
Products Directive (2001/83), [18]. Development of
licensed injection-free naloxone products including nasal
sprays may thus enable future re-classiﬁcation to over-
the-counter medication [18].
Questions for future research
In our exploratory analysis of early absorption, the 2-mg i.n.
dose took, on average, 2 minutes longer than the i.m. refer-
ence (6 versus 4minutes) to reach 50%Cmax of the i.m. refer-
ence (T50%ref). It is unclearwhat implications this 2-minute
delaymay have in clinical practice, because speed of admin-
istration of the nasal spray may be quicker so that, for ex-
ample, the 2-minute delay could be offset partially or fully.
Measurement of time involved in preparing and
administering the device is largely absent from current
considerations of different naloxone formulations. An early
exception isWagner and colleagues’ ambulance study [28]
of subcutaneous naloxone: the time from arrival at
the patient’s side to dose administration was 4 minutes
(subcutaneous) versus 6 minutes (i.v.). Inclusion of these
time intervals is essential for consideration of the merits
of different routes of administration, especially in case of
layperson administration. Future studies should examine
the time to naloxone administration for different devices
when used by laypeople without medical training. Such
studies could assess whether the slightly earlier onset of
i.m. administration observed in this study may be offset
by better usability of the nasal spray.
A separate question for future research concerns the
extent to which naloxone pharmacokinetics give accurate
understanding of real-world overdose reversals. A direct
nose-to-brain connection has been proposed (whereby
nasally administered drugs might bypass systematic
circulation), but human evidence of direct drug transport
from the nose to the cerebrospinal ﬂuid is lacking [29].
Laboratory-based study of low-dose naloxone reversal of
opioid effects could elucidate the relationship between
naloxone pharmacokinetics and pharmacodynamics.
CONCLUSIONS
Taken together with other recently published data
[11,13,30], the results of this study lend strong support to
the potential value of concentrated i.n. naloxone spray for
opioid overdose reversal. Across all three i.n. doses, naloxone
exposure was dose-proportional, with approximately 50%
absolute bioavailability. We identiﬁed the 2 mg/0.1 ml i.n.
dose as most similar to the 0.4 mg i.m. reference,
producing comparable early naloxone concentrations. The
2 mg i.n. dose had the added feature of effective
maintenance of plasma levels for the next 2 hours. (In
September 2017, following acceptance of this manuscript
but pre-publication, the European Medicines Agency gave
a positive opinion to the application for product license for
a 1.8mg/0.1mL concentrated naloxone nasal spray under
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the trade name Nyxoid; 1.8mg naloxone in Nyxoid is equiv-
alent to 2mg naloxone hydrochloride).
Clinicians and policymakers will need to consider
the potentialmerits of the different time–course proﬁles (in-
cluding speed of onset and duration of effect) of i.n. versus
injectable naloxone and may also see implementation ad-
vantages with i.n. naloxone for broad-based take-home
naloxone provision.
Clinical trial registration details
EudraCT: 2015–004493-15.
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